Author Title [ Type(Desc)] Year
Filters: Author is Stock, Wendy  [Clear All Filters]
Journal Article
Kaplan LD, Maurer MJ, Stock W, Bartlett NL, Fulton N, Pettinger A, Byrd JC, Blum KA, Lacasce AS, Hsi ED, et al. Bortezomib Consolidation or Maintenance Following Immunochemotherapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: CALGB/Alliance 50403. Am J Hematol. 2020.
DeFilipp Z, Advani AS, Bachanova V, Cassaday RD, DeAngelo DJ, Kebriaei P, Rowe JM, Seftel MD, Stock W, Tallman MS, et al. Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.
Kantarjian HM, DeAngelo DJ, Stelljes M, Liedtke M, Stock W, Gökbuget N, O'Brien SM, Jabbour E, Wang T, White JLiang, et al. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019.
Christian S, Arain S, Patel P, Khan I, Calip GS, Agrawal V, Sweiss K, Griffin S, Cahill K, Konig H, et al. A Multi-institutional Comparison of Mitoxantrone, Etoposide, and Cytarabine (MEC) versus High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Am J Hematol. 2020.
Marks DI, Kebriaei P, Stelljes M, Gökbuget N, Kantarjian H, Advani AS, Merchant A, Stock W, Cassaday RD, Wang T, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019.
Derman BA, Kordas K, Ridgeway J, Chow S, Dale W, Lee SMee, Aguada E, Jakubowiak AJ, Jasielec J, Kline J, et al. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019;3(22):3488-3498.
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D, McCastlain K, Ding L, Lu C, Song G, et al. Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia. N Engl J Med. 2014;371(11):1005-1015.
Wang AY, Kline J, Stock W, Kosuri S, Artz A, Larson RA, Riedell PA, Bishop M, Liu H. Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation: Toxicities with maintenance nivolumab after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2020.